Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.33 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.32 |
| ▸ | RAF1 | P04049 | 3/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31696465 | 0.92 | KCNT1 (0.34) | RIPK1PDE10AKCNT1CRACR2ARAF1 | |
| SCHEMBL31696380 | 0.84 | KCNT1 (0.40) | RIPK1KCNT1RAF1USP30PDE4B | |
| SCHEMBL31696419 | 0.80 | GPR119 (0.35) | HCRTR1CRACR2ARAF1GPR65 | |
| SCHEMBL31696629 | 0.80 | KCNT1 (0.37) | RIPK1KCNT1RAF1USP30BRAF | |
| SCHEMBL31696538 | 0.79 | HPGDS (0.41) | KCNT1RAF1BRAF | |
| SCHEMBL31696554 | 0.79 | RIPK1 (0.35) | RIPK1 | |
| SCHEMBL31696433 | 0.79 | KCNT1 (0.46) | KCNT1CRACR2ARAF1BRAF | |
| SCHEMBL31696387 | 0.77 | HCRTR1 (0.33) | HCRTR1CRACR2AGPR65 | |
| SCHEMBL31696519 | 0.76 | KCNT1 (0.40) | RIPK1KCNT1RAF1BRAFPDE4B | |
| SCHEMBL31696600 | 0.74 | CCNT1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | ACTIO BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | ACTIO BIOSCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313548-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS | KCNT1, KCNT2, KCNN3 | RIPK1 3532/4885HCRTR1 3005/4885PDE10A 1098/4885 |
| US-12630533-B2 | Heterocyclic compounds useful as KCNT1 inhibitors | KCNT1, KCNT2, KCNJ2 | RIPK1 2929/4885HCRTR1 1556/4885PDE10A 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.